$370 Million is the total value of Sio Capital Management, LLC's 70 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 62.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $10,483,000 | +27.9% | 62,186 | -26.1% | 2.83% | -5.2% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $7,397,000 | -34.4% | 79,153 | -48.8% | 2.00% | -51.4% |
| MEIP | Sell | MEI PHARMA INC | $7,235,000 | +15.4% | 2,356,633 | -0.7% | 1.95% | -14.5% |
| SNY | Sell | SANOFI SAsponsored adr | $6,945,000 | -40.4% | 156,854 | -41.6% | 1.88% | -55.8% |
| RIGL | Sell | RIGEL PHARMACEUTICALS INC | $4,136,000 | -17.5% | 1,609,265 | -26.2% | 1.12% | -38.9% |
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $3,831,000 | +5.1% | 30,000 | -14.6% | 1.03% | -22.1% |
| PEN | Sell | PENUMBRA INCput | $3,528,000 | -15.1% | 24,000 | -29.4% | 0.95% | -37.0% |
| HUM | Sell | HUMANA INC | $2,877,000 | -38.4% | 10,817 | -33.7% | 0.78% | -54.3% |
| UROV | Sell | UROVANT SCIENCES LTD | $2,161,000 | -59.4% | 215,042 | -73.4% | 0.58% | -69.9% |
| ACHV | Sell | ACHIEVE LIFE SCIENCES INC | $1,361,000 | +88.2% | 421,479 | -29.4% | 0.37% | +39.5% |
| HRC | Sell | HILL-ROM HOLDINGS INC | $1,025,000 | -53.1% | 9,682 | -60.8% | 0.28% | -65.2% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $603,000 | -43.9% | 42,410 | -88.9% | 0.16% | -58.3% |
| RMED | Sell | RA MEDICAL SYSTEMS INC | $590,000 | -84.7% | 173,652 | -64.3% | 0.16% | -88.7% |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -25,900 | -100.0% | -0.14% | – |
| CFMS | Exit | CONFORMIS INC | $0 | – | -1,121,894 | -100.0% | -0.15% | – |
| TMDI | Exit | TITAN MEDICAL INC | $0 | – | -445,680 | -100.0% | -0.20% | – |
| VCYT | Exit | VERACYTE INC | $0 | – | -70,199 | -100.0% | -0.32% | – |
| IVC | Exit | INVACARE CORP | $0 | – | -247,196 | -100.0% | -0.39% | – |
| ESTA | Exit | ESTABLISHMENT LABS HOLDINGS INC | $0 | – | -52,701 | -100.0% | -0.53% | – |
| PHG | Exit | KONINKLIJKE PHILIPS NVny reg sh new | $0 | – | -50,000 | -100.0% | -0.64% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -144,411 | -100.0% | -0.74% | – |
| XRAY | Exit | DENTSPLY SIRONA INC | $0 | – | -65,666 | -100.0% | -0.89% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -50,000 | -100.0% | -0.95% | – |
| AMGN | Exit | AMGEN INC | $0 | – | -17,000 | -100.0% | -1.20% | – |
| ABT | Exit | ABBOTT LABORATORIES | $0 | – | -48,737 | -100.0% | -1.28% | – |
| BDX | Exit | BECTON DICKINSON AND CO | $0 | – | -16,000 | -100.0% | -1.31% | – |
| ALGN | Exit | ALIGN TECHNOLOGY INC | $0 | – | -17,847 | -100.0% | -1.36% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -69,000 | -100.0% | -1.80% | – |
| PINC | Exit | PREMIER INCcl a | $0 | – | -134,412 | -100.0% | -1.83% | – |
| MYL | Exit | MYLAN NV | $0 | – | -187,175 | -100.0% | -1.87% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -102,390 | -100.0% | -2.39% | – |
| CAH | Exit | CARDINAL HEALTH INC | $0 | – | -209,009 | -100.0% | -3.40% | – |
| AMGN | Exit | AMGEN INCput | $0 | – | -50,000 | -100.0% | -3.55% | – |
| CI | Exit | CIGNA CORP | $0 | – | -52,216 | -100.0% | -3.61% | – |
| ABC | Exit | AMERISOURCEBERGEN CORP | $0 | – | -133,934 | -100.0% | -3.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.